182 results about "Immunoadjuvant" patented technology

Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.

The present invention relates to immunological adjuvants comprised of the N-formyl methionyl peptide fMLP. FMLP, when used as an adjuvant in accordance with the present invention, provides for an immune response to suboptimal doses of recombinant antigens.

Adjuvant combinations comprising at least one microbial TLR agonist such as a whole virus, bacterium or yeast or portion thereof such a membrane, spheroplast, cytoplast, or ghost, a CD40 or 4-1BB agonist and optionally an antigen wherein all 3 moieties may be separate or comprise the same recombinant microorganism or virus are disclosed. The use of these immune adjuvants for treatment of various chronic diseases such as cancers and HIV infection is also provided.

Fusion proteins and DNA conjugates are disclosed which contain a TLR/CD40/agonist and optional antigen combination. The use of these protein and DNA conjugates as immune adjuvants and as vaccines for treatment of various chronic diseases such as HIV infection is also provided.

The invention relates to cell stimulatory fusion proteins and DNA sequences, vectors comprising at least two agonists of TNF/TNFR super family, immunoglobulin super family, cytokine family proteins and optional antigen combination. Instructions for use of these proteins and DNA constructs as immune adjuvants and vaccines for treatment of various chronic diseases such as viral infection are also provided. Additionally, the use of these protein and DNA constructs as immune suppressant for treatment of various chronic diseases, such as autoimmunity and organ transplant rejection, is also illustrated.

Addition of a bacterial ADP-ribosylating exotoxin (bARE) to a formulation (e.g., immunogen or vaccine) or a system (e.g., patch or kit) for immunization enhances the immune response in a subject to one or more components of the formulation. Binding of the B subunit of a bARE to ganglioside GM1 of the subject in vivo, however, mediates toxicity and limits the use of native bARE as adjuvants. Mutation or in vitro coupling of the B subunit to ligands such as GM1 inhibits binding to GM1 in vivo, thereby eliminating toxicity but retaining desired adjuvant activity. The use of such detoxified, GM-1 binding deficient exotoxins provides a safe and potent new strategy for development of effective formulation for immunization.

Immuno-adjuvant photodynamic therapy to treat and prevent metastatic cancer is effected using photosensitizers in combination with immuno-adjuvants to destroy metastatic tumor cells.

An immunoadjuvant used to prepare the antiviral vaccine or medicine for increasing the immune activity of the antigens for HBV, HCV, SARS coronavirus, fowl influenza virus, etc is a kind of human or animal's novel heat shock proteins gp96, hsp108 and hsp70.

Plasmid adjuvant compositions and methods for enhancing an immune response to a coadministered immunogen are described. The plasmid adjuvants include a combination of cytokines and chemokines designed to elicit an enhanced immune response. Particular combinations can be provided to generate a Th1 and/or a Th2 immune response.

This invention relates to a method for preparing immunogen G17CRM197 containing diphtherin mutant CRM197 as carrier. The method comprises: crosslinking diphtherin mutant CRM197 with gastrin G17 through epsiv-maleimidyl caproic acid N-hydroxysuccinimide eater (EMCS). Diphtherin mutant CRM197 is used as a carrier, and has such advantages as high recovery rate and easy purification. The method has such advantages as high product crosslinking rate, short preparation time, and low cost. Immunogen G17CRM197 can be used as an effective component in therapeutic vaccines, or used in anti-tumor drugs with appropriate immunoadjuvants.

A method of screening for agents that stimulate the innate immune system in mammals employs markers that respond to Toll-like receptor binding. Agents identified in the assay boost both innate and adaptive immune responses, when administered alone or in combination with vaccines.

The invention provides a short peptide, application of the short peptide as a vaccine adjuvant, and a vaccine using the short peptide as the vaccine adjuvant. The short peptide is simple to prepare and can improve immune response of antigen after simple physical mixing with the antigen. The sequence of the short peptide is X-GFFYK, wherein X is a terminating group. Preferably, the short peptide is of D configuration. The short peptide can be used as an immunoadjuvant to improve immunogenicity of antigen and allows a main body to undergo intense antigen-specific cellular immune and humoral immune response; the short peptide is applicable to a variety of antigens; and the short peptide is easy to prepare and has a single and controllable component.

An immunoadjuvant which can efficiently exhibit potent adjuvant activity and avoid conditions undesirable for living bodies, and comprises precipitates formed by coacervation of (a) a soluble protein (provided that a soluble protein contained in tuberculin is excluded), and (b) a mucopolysaccharide, and further comprises (c) a soluble protein contained in tuberculin wherein said (c) is coprecipitated with the precipitates.

Methods for enhancing the immune response of a subject to an immunoeffector, and methods of enhancing interleukin-12 production, which are effected by administering an amount of the immunoeffector and an effective adjuvanting amount of a tellurium-containing compound are provided. The enhanced immune response may be a cell-mediated or a humoral immune response. A pharmaceutical composition, which comprises the tellurium-containing compound, the immunoeffector and a pharmaceutically acceptable carrier is also provided. Use of a tellurium-containing compound as an adjuvant for immunization is also provided.

The invention belongs to the technical field of biology, and relates to an allergic asthma model, in particular to application of chitosan serving as immuno-adjuvant in preparing a mouse allergic asthma model. According to the application, the mouse allergic asthma model prepared by applying chitosan serving as immuno-adjuvant is subjected to airway responsiveness, lung tissue pathological examination and inflammation marker inspection, and results indicate that the mouse allergic asthma model prepared by applying chitosan serving as immuno-adjuvant is remarkably superior to a conventional immuno-adjuvant prepared asthma model in airway eosinophilic inflammation, airway responsiveness and airway inflammatory cytolines and other aspects. The chitosan has low price and rich sources; and the mouse asthma model by using chitosan as immuno-adjuvant is remarkably superior to a traditional adjuvant, and has the advantages of simple method, low cost, good reproducibility and the like.

The invention discloses a method for synthesizing a swainsonine antigen, comprising the following steps of: firstly performing a reaction between halo alkyl aryl fatty acid and alcohol to generate halo alkyl aryl fatty acid ester, followed by a reaction between halo alkyl aryl fatty acid ester and swainsonine to generate a quaternary ammonium salt with a structure of aromatic nucleus, performing a reaction between the quaternary ammonium salt and sodium hydroxide for deesterification to generate a sodium salt, adjusting the pH value by the use of hydrochloric acid to generate SW-halo alkyl aryl fatty acid; condensing SW-halo alkyl aryl fatty acid with bovine serum albumin (BSA) to produce SW-BSA, sieving through a glucan gel column chromatography for desalination, freeze drying, determining the proportion of BSA and SW, and adding an immunoadjuvant for emulsification to obtain the SW immune antigen. The antigen is white and oily with the effective content being 5mg/mL and the effective immune period being 12 months. The effective protection rate reaches more than 90%.

The present invention provides (poly)peptides, which are recognized by human cytomegalovirus (CMV)-specific immune cells. The present invention further provides a combination of multiple CMV (poly)peptides, comprising at least two different groups of (poly)peptides according to the invention as well as conjugates, comprising said (poly)peptides and/or immune adjuvants thereof. Furthermore, this invention provides mixtures, comprising said (poly)peptides and/or immune cells thereof, which are used to generate CMV-specific immune effector cells with high sensitivity and specificity. In addition, the present invention provides a preparation method of CMV-specific immune effector cells, by using said (poly)peptides, adjuvants, immune cells and/or mixtures thereof to generate anti-CMV immune response.

The present invention relates to novel peptide compounds derived from flagellin originating from Salmonella enterica that exhibit an in vivo immune adjuvant activity.

The invention discloses a novel water soluble composite immune adjuvant and a porcine circovirus disease vaccine. Four aqueous adjuvants (CP974S, CP934S, CP974M, and CP) are screened and designed to prepare a PCV2 inactivated vaccine. The results of mouse immunity tests and pig immunity tests show that CP974S and CP934S have a strong immune adjuvant effect on the PCV2 inactivated vaccine, and the pig immunity protective effect of CP974S aqueous adjuvant is better than the PCV2 imported ISA206 adjuvant inactivated vaccine. A baculovirus expressed PCV2Cap recombinant protein is taken as the basis to prepare different adjuvant vaccines. The results of mouse immunity tests and pig immunity tests show that two aqueous adjuvants (CP974S and CP934S) also have a strong immunity adjuvant effect on the PCV2Cap recombinant protein and the pig immunity effect of CP974S adjuvant vaccine is better than imported PCV2Cap subunit vaccine. The CP974S aqueous adjuvant fills the gap of water soluble adjuvant for pigs in China. The developed PCV2 vaccine is safe and effect and has an important application prospect.

The invention discloses a recombinant goose interleukin-2(gsIL-2) protein preparing method and its use. The DNA fraction of RT-PCR amplified Zhedong white goose interleukin-2, prokaryotic expression carrier pBAD/HisB, and eukaryotic expression carriers pMET alpha B and pMETB compose expression particles pBAD/HisB/gsIL-2, pMET alpha B/gsIL-2 and pMETA/gsIL-2, which are converted to Escherichia coli LMG194, microzyme PMAD11 and PMAD16, respectively, then inducing expression. After inducing, making ultrasonic wave cracking and deposit elimination by centrifugation on Escherichia coli and microzyme PMAD16 to obtain crude products of gsIL-2 protein, PMAD11 expressed gsIL-2 is mainly separated in the culture medium, centrifugating and taking supernatant to obtain gsIL-2 protein crude products. Using Ni-NTAArgarrose protein purifying system, thus able to faster obtain gsIL-2 pure product, and the crude and pure products can act as immune assistant and disease-curing drugs. It applied genetic engineering technique to prepare recombinant protein gsIL-2, and has simple technical flow, low production cost, good stability, high bioactivity and other characters.

Disclosed is a composition comprising, as an active ingredient, at least one selected from the group consisting of a Zc3h12a gene inhibitor and a Zc3h12a protein inhibitor. This composition can be used as an immunoadjuvant.